Company	FR docket	Published
Chattem Chemicals	83 FR 56103	November 9, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a

registration as a bulk manufacturer to the above listed company.

Dated: January 29, 2019.

#### John J. Martin,

Assistant Administrator.

[FR Doc. 2019-02867 Filed 2-20-19; 8:45 am]

BILLING CODE 4410-09-P

#### **DEPARTMENT OF JUSTICE**

# Drug Enforcement Administration [Docket No. DEA-392]

#### Bulk Manufacturer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and been granted registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on a previously published notice is listed below. No comments or objections were submitted for the notice.

Company	FR docket	Published
Janssen Pharmaceuticals, Inc	83 FR 55205	November 2, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a

registration as a bulk manufacturer to the above listed company.

Dated: January 7, 2019.

#### John J. Martin,

Assistant Administrator.

[FR Doc. 2019–02868 Filed 2–20–19; 8:45 am]

BILLING CODE 4410-09-P

### **DEPARTMENT OF JUSTICE**

# Drug Enforcement Administration [Docket No. DEA-392]

## Importer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule I or schedule II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on the previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR docket	Published
Mylan Pharmaceuticals, Inc	83 FR 64158 83 FR 64158	December 13, 2018. December 13, 2018.

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company's maintenance of effective controls

against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted registrations as importers for schedule II controlled substances to the above listed companies.

Dated: January 29, 2019.

### John J. Martin,

Assistant Administrator.

[FR Doc. 2019–02874 Filed 2–20–19; 8:45 am]

BILLING CODE 4410-09-P